Makoto Maemondo

	Morioka Ingelheim

	Akira Inoue Koichi EGFR Takashi Seto Toyoaki Hida Hiroshi Kazuhiko Nishio Phase Shunichi Cancer Center Gefitinib Kazuhiro

Images of Makoto Maemondo

(0 from 0 )

News

Tarceva May Improve Survival From Lung Cancer

www.webmd.com

Patients whose advanced lung cancers bear the EGFR mutation survive 2 to 3 times longer if given initial treatment with Tarceva.

Gefitinib Extends Life in Lung Cancer Patients With Mutation...

www.doctorslounge.com

Makoto Maemondo, M.D., of the Miyagi Cancer Center in Japan, and colleagues randomly assigned 230 patients with metastatic NSCLC, who ...

First-line gefitinib doubled PFS in NSCLC with mutated EGFR

www.healio.com

... inhibitor as first-line treatment in patients with NSCLC and sensitive EGFR mutations,” wrote the researchers, led by Makoto Maemondo, MD, ...

Network Profiles

Facebook: Makoto Maemondo | Facebook

Facebook: Makoto Maemondo - Facebook

Makoto Maemondo. Makoto Maemondo is on Facebook. To connect with Makoto, sign up for Facebook today. Sign Up Log In. Makoto Maemondo likes: ...

Facebook: Makoto Maemondo Profiles | Facebook

Makoto Maemondo on Facebook. Join Facebook to connect with Makoto Maemondo and others you may know. Facebook ...

pinterest.com: Makoto Maemondo

0 Pins • 0 Followers

Interests

Lancet Oncology, The - Présentation - EM consultewww.em-consulte.com › article › durvalumab-as-third-l...

www.em-consulte.com

Luis Paz-Ares Rodriguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang-We Kim, Jamie Chaft, David ...

Lancet Oncology, The - Vol n° 7 - EM consulte

www.em-consulte.com

Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, ...

Business Profiles

Researchgate: Makoto Maemondo

Morioka, Iwate, Japan

Education

EGFR mutation-positive

www.simply4doctors.be

Makoto Maemondo, M.D.. N Engl J Med 2010;362: Treatment after Protocol Discontinuation. Gefitinib n=114. Carboplatin–Paclitaxel n=114. n=37. n=77.

Books & Literature

Makoto Maemondo | XanEdu Customization Platform

www.academicpub.com

Author: Makoto Maemondo. Results. Rapidly progressive primary adenocarcinoma of the lung with signet-ring cells responding to 5-fluorouracil and leucovorin: ...

www.scinapse.io

Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer ...

Scientific Publications

(1 - 4 from 11

–show all

)

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive...

pubmed.ncbi.nlm.nih.gov

... Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; Toyoaki Hida, ...

Efficacy and safety of nivolumab in Japanese patients with advanced...

www.ncbi.nlm.nih.gov

Makoto Maemondo received research funding from Boehringer Ingelheim. Maemondo M. also received honoraria from Bristol‐Myers Squibb, ...

Loss of protein phosphatase 6 in mouse keratinocytes increases...

www.sciencedirect.com

Yoichiro Kakugawa a, Yoji Yamashita a, Koh Miura a, Makoto Maemondo d,. Ryuichi Katakura a, Shigemi Ito e, Masami Sato f, Ikuro Sato e, Natsuko Chiba g,.

Respiratory Investigation | Journal | ScienceDirect.com

www.sciencedirect.com

Affiliations. Department of Respiratory Medicine, Miyagi Cancer Center, Nodayama, Medeshima-shiote, NatoriJapan. ,. Makoto Maemondo.

Publications

(1 - 4 from 9

–show all

)

Makoto Maemondo | PubFacts

www.pubfacts.com

Makoto Maemondo

EGFR Mutation Analysis of Circulating Tumor DNA Using an ...www.hindawi.com › journals › crj

www.hindawi.com

... Tatsuro Fukuhara,1 Yoko Tsukita,1 Mami Morita,1 Aya Suzuki,1 Nobuyuki Tanaka,2 Hiroshi Terasaki,3 Toshihiro Nukiwa,4 and Makoto Maemondo 1.

Japanese subgroup analysis of a phase III study of S-1 versus...

link.springer.com

Makoto Maemondo. Department of Cancer Information Research, National Kyushu Cancer Center, Clinical Research Institute, Fukuoka, Japan.

Effectiveness of Gefitinib against Non–Small-Cell BioMedSearch

www.biomedsearch.com

Makoto Maemondo, MD, PhD,‡ Akira Inoue, MD, PhD,§ Shunichi Sugawara, MD, PhD,║. Hiroshi Isobe, MD, PhD,¶ Masao Harada, MD, PhD,# Yoshiki Ishii, MD, ...

Reports & Statements

(1 - 4 from 6

–show all

)

Tumor suppression effect using NK4, a molecule acting as an...

www.nature.com

Preliminary Report

[ASCO 2014] Câncer de Pulmão - Manual de Oncologia Clínica do Brasil

mocbrasil.com

Author(s): Akira Inoue, Yukio Hosomi, Makoto Maemondo, et al. This randomized phase III trial was designed to compare the efficacy and safety ...

Preliminary reports Tumor suppression effect using NK4, a Nature

www.nature.com

Makoto Maemondo,. 2. Toshihiro Nukiwa,. 2. Kunio Matsumoto,. 3. Toshikazu Nakamura,. 3 and Yoshiyuki Nakajima First Department of Surgery, Nara ...

N-terminal deletion augments the cell-death-inducing activity of BAX...

www.nature.com

Original Paper

Miscellaneous

(1 - 20 from 39

–show all

)

Etude JO de phase III en première ligne, erlotinib et...

slideplayer.fr

Author(s): Terufumi Kato, Takashi Seto, Makoto Nishio, Koichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko ...

Makoto Maemondo | Publonspublons.com › researcher › makoto-maemondo

publons.com

View Makoto Maemondo's profile on Publons with 3 reviews Research Fields. Makoto Maemondo has not yet added any research fields to their profile.

Joint Diseases: Maemondo, Makoto - Expertscape.com

www.expertscape.com

Medical and scientific articles about Joint Diseases, written by Makoto Maemondo

Methicillin-Resistant Staphylococcus aureus: Maemondo, Makoto -...

www.expertscape.com

Makoto Maemondo has special expertise in Methicillin-Resistant Staphylococcus aureus

Makoto Maemondo

www.infona.pl

Maemondo, Akira Inoue, Osamu Ishimoto, more · Respiratory ...

ASCO Reading Room | Three-Year Follow-Up of an Alectinib Phase I/II...

www.medpagetoday.com

Tomohide Tamura, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Hiroshige Yoshioka, ...

Addition of Bevacizumab to Erlotinib Improves Progression ...www.ascopost.com › issues › june › addition-...

ascopost.com

Makoto Maemondo, MD. In an interim analysis of the phase III NEJ026 trial reported in The Lancet Oncology, Makoto Maemondo, MD, and ...

Makoto Maemondo | Admin Project Alpha

admin.alpha.intstrux.com

Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical ...

Bevacizumab–erlotinib improves PFS in advanced EGFR ...oncology.medicinematters.com › bevacizumab-erlotini...

oncology.medicinematters.com

Makoto Maemondo (Iwate Medical University School of Medicine, Morioka, Japan) and colleagues report the findings from an interim analysis ...

Alectinib geeft uitstekende overall overleving (75 procent) op drie...

kanker-actueel.nl

... Fukuoka; Kazuhiko Nakagawa, Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; ...

Japanese subgroup analysis of a phase III study of S-1 versus...

kyushu-u.pure.elsevier.com

... Toshiaki Takahashi, Koichi Goto, Makoto Maemondo, Yukito Ichinose, Takashi Seto, Hiroshi Sakai, Akihiko Gemma, Fumio Imamura, Masato ...

Iressa or Gefitinib for NSCL Lung Cancer

www.aboutcancer.com

Makoto Maemondo, NEJM 2010;362: Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly ...

Epidermal growth factor receptor mutation analysis in tissue ...mdanderson.elsevierpure.com › publications › epidermal-...

mdanderson.elsevierpure.com

... Makoto Maemondo, Terufumi Kato, Suzanne Jenkins, Sabina Patel, Xiangning Huang, Gianluca Laus, Aleksandra Markovets, Kenneth S. Thress, Yi Long Wu